[1] H. AA, Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment, Seminars in nephrology, 32 (2012) 40–48.
[2] C. AK, S. MJ, Y. G, B. M, H. R, K. A, L. J, R. M, T. R, W. D, O. D, L. AS, Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study, Kidney international, 65 (2004) 2380–2389.
[3] Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA, Ronco C, ADQI XI Workgroup. Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup, J Am Coll Cardiol. 2014;63:1246–52.
[4] d.J. DJ, G. DC, J. KJ, v.D. PC, T. LM, A. D, C. F, F. P, H. JG, D. M. J, W. JF, R. FR, D. FW, Cardiovascular and noncardiovascular mortality among patients starting dialysis, JAMA, 302 (2009) 1782–1789.
[5] J. F, F. N, Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology, Pharmacological reviews, 68 (2016) 49–75.
[6] B. M, B. B, J. F, Mineralocorticoid Receptor and Cardiovascular Disease, American journal of hypertension, 31 (2018) 1165–1174.
[7] F. Zannad, W. Gattis Stough, P. Rossignol, J. Bauersachs, J. J. McMurray, K. Swedberg, A.D. Struthers, A. A. Voors, L. M. Ruilope, G. L. Bakris, C. M. O’Connor, M. Gheorghiade, R. J. Mentz, A. Cohen-Solal, A. P. Maggioni, F. Beygui, G. S. Filippatos, Z. A. Massy, A. Pathak, I. L. Pina, H. N. Sabbah, D. A. Sica, L. Tavazzi, B. Pitt, Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice, Eur Heart J, 33 (2012) 2782–2795.
[8] G. M. Feniman-De-Stefano, S. G. Zanati-Basan, L. M. De Stefano, P. S. Xavier, A.D. Castro, J. C. Caramori, P. Barretti, R. J. Franco, L. C. Martin, Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients, Therapeutic advances in cardiovascular disease, 9 (2015) 158–167.
[9] Y. Matsumoto, Y. Mori, S. Kageyama, K. Arihara, T. Sugiyama, H. Ohmura, T. Yakushigawa, H. Sugiyama, Y. Shimada, Y. Nojima, N. Shio, Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients, Journal of the American College of Cardiology, 63 (2014) 528–536.
[10] C. Lin, Q. Zhang, H. Zhang, A. Lin, Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study, Journal of clinical hypertension (Greenwich, Conn.), 18 (2016) 121–128.
[11] R. Lee, M. Yin, Z. He, H. Gurm, M. Heung, Dialysis paradox: impact of aldosterone antagonism on survival in patients with HF and ESRD. Heart Failure and Cardiomyopathies, 73 (2019) 924.
[12] Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G, Chen J. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study, J Clin Hypertens (Greenwich). 2014;16:658–63.
[13] J. P. Higgins, S. G. Thompson, J. J. Deeks, D. G. Altman, Measuring inconsistency in meta-analyses, BMJ (Clinical research ed.), 327 (2003) 557–560.
[14] Y. Ito, M. Mizuno, Y. Suzuki, H. Tamai, T. Hiramatsu, H. Ohashi, I. Ito, H. Kasuga, M. Horie, S. Maruyama, Y. Yuzawa, T. Matsubara, S. Matsuo, Long-term effects of spironolactone in peritoneal dialysis patients, Journal of the American Society of Nephrology: JASN, 25 (2014) 1094–1102.
[15] A. Vukusich, S. Kunstmann, C. Varela, D. Gainza, S. Bravo, D. Sepulveda, G. Cavada, L. Michea, E. T. Marusic, A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients, Clinical journal of the American Society of Nephrology: CJASN, 5 (2010) 1380–1387.
[16] L. L, L. SM, M. S, L. M. A, E. M. S, P. S, B. NA, K. P, J. F, B.-C. J, Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress, Hypertension (Dallas, Tex.: 1979), 69 (2017) 870–878.
[17] J. Barrera-Chimal, L. Rocha, I. Amador-Martínez, R. Pérez-Villalva, R. González, C. Cortés-González, N. Uribe, V. Ramírez, N. Berman, G. Gamba, N. A. Bobadilla, Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 34 (2019) 794–801.
[18] G. C, M.-V. D, M. GP, T. MF, Y. TM, O. EM, K. T, L. N, P. L, W. GH, R. V, A. GK, Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus, Endocrinology, 147 (2006) 5363–5373.
[19] M. FY, H. Y, N.-P. DJ, K. P, T. GH, Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR–4628, PloS one, 10 (2015) e0145666.
[20] M. Ojeda-Cervantes, J. Barrera-Chimal, J. Alberu, R. Perez-Villalva, L. E. Morales-Buenrostro, N. A. Bobadilla, Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study, American journal of nephrology, 37 (2013) 481–490.
[21] B. ER, R. R, R. AE, B. EA, P. ML, M. EG, Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats, Kidney international, 63 (2003) 1791–1800.
[22] K. Sánchez-Pozos, J. Barrera-Chimal, J. Garzón-Muvdi, R. Pérez-Villalva, R. Rodríguez-Romo, C. Cruz, G. Gamba, N. A. Bobadilla, Recovery from ischemic acute kidney injury by spironolactone administration, Nephrology Dialysis Transplantation, 27 (2012) 3160–3169.
[23] C. L, M.-M. E, M. M, C. V, R. E, S. JR, Z. F, R. P, L.-A. N, The impact of galectin–3 inhibition on aldosterone-induced cardiac and renal injuries, JACC. Heart failure, 3 (2015) 59–67.
[24] K. Quach, L. Lvtvyn, C. Baigent, J. Bueti, A. X. Garg, C. Hawley, R. Haynes, B. Manns, V. Perkovic, C. G. Rabbat, R. Wald, M. Walsh, The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis, American journal of kidney diseases: the official journal of the National Kidney Foundation, 68 (2016) 591–598.
[25] D. S. Raj, J. Y. Hsu, A. H. Anderson, A.M. Hung, M. DiCarli, P. L. Kimmel, A. S. Kliger, L. M. Dember, A. Kliger, D. M. Charytan, et al., Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial, Kidney international, (no pagination) (2018).
[26] F. Hammer, U. Malzahn, J. Donhauser, C. Betz, M. P. Schneider, C. Grupp, N. Pollak, S. Stork, C. Wanner, V. Krane, A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients, Kidney international, 95 (2019) 983–991.
[27] Z. F, A. F, D. B, P. A, P. B, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators, Circulation, 102 (2000) 2700–2706.
[28] B.-C. J, G. S, J. F, Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis, Kidney international, undefined (2019) undefined.
[29] M. Walsh, B. Manns, A. X. Garg, J. Bueti, C. Rabbat, A. Smyth, J. Tyrwhitt, J. Bosch, P. Gao, P. J. Devereaux, R. Wald, The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial, Clinical journal of the American Society of Nephrology: CJASN, 10 (2015) 1602–1608.
[30] S. Taheri, M. Mortazavi, S. Shahidi, A. Pourmoghadas, M. Garakyaraghi, S. Seirafian, A. Eshaghian, M. Ghassami, Spironolactone in chronic hemodialysis patients improves cardiac function, Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 20 (2009) 392–397.
[31] G. M. M. Feniman-De-Stefano, S. G. Zanati-Basan, L. M. De Stefano, P. S. Xavier, A.D. Castro, J. C. T. Caramori, P. Barretti, R. Jorge Da Silva Franco, L. C. Martin, Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients, Therapeutic advances in cardiovascular disease, 9 (2015) 158–167.